Oxygen Biotherapeutics, Inc. (OXBT)
-NasdaqCM 4.40 
0.12(2.80%) May 17, 3:55PM EDT
| Prev Close: | 4.28 |
|---|
| Open: | 4.17 |
|---|
| Bid: | N/A |
|---|
| Ask: | 4.75 x 200 |
|---|
| 1y Target Est: | 3.00 |
|---|
| Beta: | -0.17 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 4.00 - 4.40 |
|---|
| 52wk Range: | 0.18 - 2.25 |
|---|
| Volume: | 6,177 |
|---|
| Avg Vol (3m): | 306,049 |
|---|
| Market Cap: | 168.54M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -7.86 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Oxygen Biotherapeutics Receives Favorable NASDAQ Listing DecisionBusiness Wire(Thu, May 16)
- OXYGEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Thu, May 16)
- OXYGEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, OthEDGAR Online(Wed, May 15)
- Oxygen Biotherapeutics Announces 20:1 Reverse Stock Split Effective After Market Close on May 10thBusiness Wire(Fri, May 10)
- OXYGEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Wed, May 1)
- Oxygen Biotherapeutics to begin enrollment in second cohort of STOP-TBI trialat theflyonthewall.com(Tue, Apr 30)
- Oxygen Biotherapeutics Announces It is Set to Begin Enrolling Patients in the Second Cohort of Its STOP-TBI Clinical Trial in IsraelBusiness Wire(Tue, Apr 30)
- OXYGEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule oEDGAR Online(Fri, Apr 5)
- OXYGEN BIOTHERAPEUTICS, INC. FinancialsEDGAR Online Financials(Fri, Mar 22)
- OXYGEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule oEDGAR Online(Thu, Mar 21)
- Oxygen Biotherapeutics, Inc. Earnings Call scheduled for 11:00 am ET todayCCBN(Tue, Mar 19)
- OXYGEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatementsEDGAR Online(Tue, Mar 19)
- Oxygen Biotherapeutics Reports Financial Results for the Third Quarter FY2013Business Wire(Mon, Mar 18)
- OXYGEN BIOTHERAPEUTICS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Mon, Mar 18)
- Q3 2013 Oxygen Biotherapeutics, Inc. Earnings Release - Time Not SuppliedCCBN(Mon, Mar 18)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 145.72 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Apr-13)
: | N/A |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | 3.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Oxygen Biotherapeutics, Inc., a development stage company, engages in developing biotechnology products that deliver oxygen to target tissues in the body primarily in the United States.
View More